Stemline Therapeutics has developed a Discovery Platform called "StemScreen®" to identify novel compounds that target and kill CSCs.
StemScreen® 1 is a 3-step platform which involves:
- CSC isolation and target identification.
- Proprietary in silico screen which identifies compound classes that interact with CSC targets.
- Battery of anti-CSC functional assays that test compounds for activity against CSCs both in vitro and in vivo. In some cases the Company has employed medicinal chemistry to optimize lead compounds. Stemline currently has 6 active oncology programs — three of which have yielded lead compounds to date.
StemScreen® 2 is a proprietary high throughput screen currently in development. StemScreen® 2 takes advantage of a landmark discovery that cancer cell lines harbor CSCs. Stemline has exclusively licensed the technology derived from this discovery from the University of Cambridge which enables the development of high throughput screens for compounds that target CSCs.
|
